NCT03774654View on ClinicalTrials.gov

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

June 20, 2026

Study Completion Date

February 28, 2035

Conditions
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALLRelapsed CLLRelapsed Non Hodgkin Lymphoma
Interventions
GENETIC

CD19.CAR-aNKT cells

"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Baylor College of Medicine

OTHER